Combination therapy reveals potential vulnerability in aggressive osteosarcoma

Scientists co-led by St. Jude Children's Research Hospital person identified a imaginable therapeutic vulnerability successful immoderate forms of osteosarcoma. A operation attack described contiguous successful the Journal of Experimental Medicine slowed tumor maturation and prolonged endurance successful preclinical models of this pediatric bony cancer. The therapies degraded EP300 (a macromolecule that is co-opted to explicit oncogenes successful galore cancers) and inhibited AKT (a well-known crab cause target), highlighting the combination's objective potential.